Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
huanglong heji
- Development stage
- Unknown
- Administration
- Oral
01
Overview
Huanglong Heji (黄龙合剂) is a traditional Chinese medicine (TCM) compound preparation used primarily for the treatment of pediatric cough variant asthma and related respiratory conditions. It is a multi-herb formulation, typically administered as an oral liquid, and is designed to relieve symptoms such as cough and wheezing. Network pharmacology studies suggest that its mechanism involves inhibition of IL-4-mediated p-STAT6 nuclear translocation, indicating immunomodulatory effects relevant to allergic airway inflammation[2]. The specific herbal components may vary by manufacturer but generally target anti-inflammatory pathways and immune regulation.
- Other names
- 黄龙合剂
02
Targets
STAT6 (Signal Transducer and Activator of Transcription 6)
Beyond the preview
Go deeper on huanglong heji.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on huanglong heji.